Lived experience of State-sponsored intra-national overseas therapeutic mobility for stem cell transplantation.

Bone marrow graft Cancer France Haematopoietic stem cell transplantation La Réunion Lived experience Overseas Therapeutic mobility

Journal

Social science & medicine (1982)
ISSN: 1873-5347
Titre abrégé: Soc Sci Med
Pays: England
ID NLM: 8303205

Informations de publication

Date de publication:
05 2022
Historique:
received: 20 10 2021
revised: 29 03 2022
accepted: 30 03 2022
pubmed: 10 4 2022
medline: 7 6 2022
entrez: 9 4 2022
Statut: ppublish

Résumé

This article focuses on the lived experience of patients with haematological cancer who were transferred from La Réunion (a French overseas Department) to mainland France to undergo allogeneic haematopoietic stem cell transplantation (allo-HSCT). Based on a qualitative study conducted between February 2020 and January 2021 with allo-HSCT recipients, their family caregivers and healthcare professionals, we examined the social, economic and cultural factors shaping the patients' complex experience. We have called this kind of State-sponsored intra-national medical transfer "overseas therapeutic mobility". The patients' experience of this therapeutic journey beyond their geographical and cultural frontiers has some similarities with transnational therapeutic mobility. Overseas therapeutic mobility to undergo highly technical treatment requires considerable logistic efforts and mobility skills. The remoteness of their families and their affective and cultural environment give mobile patients a feeling of disorientation and causes them much social suffering. The two-fold condition of being a sick person with a possibly lethal disease and being treated overseas can be regarded as a double ordeal. In addition, the unfunded costs place a heavy burden on the patients and those whose families have limited resources. This study points to the cleavages which occur between post-colonial overseas regions and mainland France, and the territorial inequalities existing in patients' access to specialized treatment due to French policies of healthcare centralization.

Identifiants

pubmed: 35397418
pii: S0277-9536(22)00263-5
doi: 10.1016/j.socscimed.2022.114957
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

114957

Informations de copyright

Copyright © 2022 Elsevier Ltd. All rights reserved.

Auteurs

Loreley Franchina (L)

Aix Marseille Univ., INSERM, IRD, SESSTIM, ISSPAM, Marseille, France.

Aline Sarradon-Eck (A)

Aix Marseille Univ., INSERM, IRD, SESSTIM, ISSPAM, Marseille, France; Institut Paoli-Calmettes, CanBios, UMR1252, Marseille, France. Electronic address: aline.sarradon@inserm.fr.

Yolande Arnault (Y)

Institut Paoli-Calmettes, Département de Psychologie Clinique, Marseille, France.

Anne-Gaëlle Le Corroller (AG)

Aix Marseille Univ., INSERM, IRD, SESSTIM, ISSPAM, Marseille, France.

Patricia Zunic (P)

Service d'hématologie et d'oncologie Médicale, CHU La Réunion, Saint Pierre, France.

Patricia Marino (P)

Aix Marseille Univ., INSERM, IRD, SESSTIM, ISSPAM, Marseille, France; Institut Paoli-Calmettes, CanBios, UMR1252, Marseille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH